Monopar Therapeutics Inc (MNPR)

$0.7699

+0.16

(+25.99%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Monopar Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 94.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 322.1%

Performance

  • $0.62
    $0.84
    $0.77
    downward going graph

    20.13%

    Downside

    Day's Volatility :27.12%

    Upside

    8.76%

    downward going graph
  • $0.27
    $1.73
    $0.77
    downward going graph

    64.43%

    Downside

    52 Weeks Volatility :84.17%

    Upside

    55.49%

    downward going graph

Returns

PeriodMonopar Therapeutics IncIndex (Russel 2000)
3 Months
-22.24%
0.0%
6 Months
147.87%
0.0%
1 Year
-19.23%
0.0%
3 Years
-86.95%
-22.6%

Highlights

Market Capitalization
10.7M
Book Value
$0.43
Earnings Per Share (EPS)
-0.53
Wall Street Target Price
2.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-48.38%
Return On Equity TTM
-92.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.4
EPS Estimate Next Year
-0.31
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Monopar Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
7
Hold
1
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 159.77%

Current $0.77
Target $2.00

Technicals Summary

Sell

Neutral

Buy

Monopar Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monopar Therapeutics Inc
Monopar Therapeutics Inc
-2.79%
147.87%
-19.23%
-86.95%
-97.09%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monopar Therapeutics Inc
Monopar Therapeutics Inc
NA
NA
NA
-0.4
-0.93
-0.48
NA
0.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Buy
$10.7M
-97.09%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Millennium Management LLC

    1.10%

  • Renaissance Technologies Corp

    0.28%

  • Vanguard Group Inc

    0.26%

  • Geode Capital Management, LLC

    0.24%

  • Gerber LLC

    0.16%

  • Virtu Financial LLC

    0.14%

Company Information

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.

Organization
Monopar Therapeutics Inc
Employees
9
CEO
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Industry
Health Technology

Discover More

FAQs